Lixte Biotechnology Holdings Net Income

The latest net income for LIXT is $-6.1B as of June 2026. That compares with $-3.1M in the prior-year period — down 196770.5% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside Lixte Biotechnology Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIXT's net income moved from $-3.1M to $-6.1B — a 196770.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lixte Biotechnology Holdings's operating scale or balance-sheet position.

Against Healthcare companies, LIXT currently prints $-6.1B for net income, while the sector average sits near $17B. That is roughly 136.8% below the sector mean. Large gaps often invite a closer look at Lixte Biotechnology Holdings's growth, margins, and balance sheet.

A net income figure of $-6.1B for LIXT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting LIXT's net income ($-6.1B), review year-over-year change from $-3.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.